PortalPublikationenRituximab removes intrarenal B cell clusters in patients wit...

Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.

Standard

Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. / Steinmetz, Oliver; Lange-Hüsken, Felix; Turner, Jan Eric; Vernauer, Almut; Helmchen, Udo; Stahl, Rolf A.K.; Thaiss, Friedrich; Panzer, Ulf.

in: TRANSPLANTATION, Jahrgang 84, Nr. 7, 7, 2007, S. 842-850.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Steinmetz, O, Lange-Hüsken, F, Turner, JE, Vernauer, A, Helmchen, U, Stahl, RAK, Thaiss, F & Panzer, U 2007, 'Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.', TRANSPLANTATION, Jg. 84, Nr. 7, 7, S. 842-850. <http://www.ncbi.nlm.nih.gov/pubmed/17984836?dopt=Citation>

APA

Steinmetz, O., Lange-Hüsken, F., Turner, J. E., Vernauer, A., Helmchen, U., Stahl, R. A. K., Thaiss, F., & Panzer, U. (2007). Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. TRANSPLANTATION, 84(7), 842-850. [7]. http://www.ncbi.nlm.nih.gov/pubmed/17984836?dopt=Citation

Vancouver

Steinmetz O, Lange-Hüsken F, Turner JE, Vernauer A, Helmchen U, Stahl RAK et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. TRANSPLANTATION. 2007;84(7):842-850. 7.

Bibtex

@article{c9516c6aee354b869cab96557bad15c8,
title = "Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.",
abstract = "BACKGROUND: Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently unclear. METHODS: We analyzed the incidence of B cell clusters in patients with vascular rejection by immunohistochemistry and compared the influence of rituximab treatment plus conventional therapy with that of conventional immunosuppression alone on intrarenal B cells. Furthermore intrarenal expression of the B cell attracting chemokine BCA-1/CXCL13 and the lymphoid chemokine SLC/CCL21 were analyzed. RESULTS: Nine of 16 patients with vascular rejection displayed intrarenal B cell clusters strictly co-localizing with expression of the B cell attractant chemokine BCA-1/CXCL13. Addition of rituximab to conventional treatment lead to complete depletion of intrarenal B cells (98.3+/-136.4 CD20, 90.7+/-113.2 CD19 vs. 0+/-0 CD20, 0+/-0 CD19 B cells/hpf, P",
author = "Oliver Steinmetz and Felix Lange-H{\"u}sken and Turner, {Jan Eric} and Almut Vernauer and Udo Helmchen and Stahl, {Rolf A.K.} and Friedrich Thaiss and Ulf Panzer",
year = "2007",
language = "Deutsch",
volume = "84",
pages = "842--850",
journal = "TRANSPLANTATION",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

RIS

TY - JOUR

T1 - Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.

AU - Steinmetz, Oliver

AU - Lange-Hüsken, Felix

AU - Turner, Jan Eric

AU - Vernauer, Almut

AU - Helmchen, Udo

AU - Stahl, Rolf A.K.

AU - Thaiss, Friedrich

AU - Panzer, Ulf

PY - 2007

Y1 - 2007

N2 - BACKGROUND: Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently unclear. METHODS: We analyzed the incidence of B cell clusters in patients with vascular rejection by immunohistochemistry and compared the influence of rituximab treatment plus conventional therapy with that of conventional immunosuppression alone on intrarenal B cells. Furthermore intrarenal expression of the B cell attracting chemokine BCA-1/CXCL13 and the lymphoid chemokine SLC/CCL21 were analyzed. RESULTS: Nine of 16 patients with vascular rejection displayed intrarenal B cell clusters strictly co-localizing with expression of the B cell attractant chemokine BCA-1/CXCL13. Addition of rituximab to conventional treatment lead to complete depletion of intrarenal B cells (98.3+/-136.4 CD20, 90.7+/-113.2 CD19 vs. 0+/-0 CD20, 0+/-0 CD19 B cells/hpf, P

AB - BACKGROUND: Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently unclear. METHODS: We analyzed the incidence of B cell clusters in patients with vascular rejection by immunohistochemistry and compared the influence of rituximab treatment plus conventional therapy with that of conventional immunosuppression alone on intrarenal B cells. Furthermore intrarenal expression of the B cell attracting chemokine BCA-1/CXCL13 and the lymphoid chemokine SLC/CCL21 were analyzed. RESULTS: Nine of 16 patients with vascular rejection displayed intrarenal B cell clusters strictly co-localizing with expression of the B cell attractant chemokine BCA-1/CXCL13. Addition of rituximab to conventional treatment lead to complete depletion of intrarenal B cells (98.3+/-136.4 CD20, 90.7+/-113.2 CD19 vs. 0+/-0 CD20, 0+/-0 CD19 B cells/hpf, P

M3 - SCORING: Zeitschriftenaufsatz

VL - 84

SP - 842

EP - 850

JO - TRANSPLANTATION

JF - TRANSPLANTATION

SN - 0041-1337

IS - 7

M1 - 7

ER -